{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:45:34Z","timestamp":1773297934755,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["40-41200-98-9269"],"award-info":[{"award-number":["40-41200-98-9269"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12888-019-2022-x","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T04:05:43Z","timestamp":1550030743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-8720","authenticated-orcid":false,"given":"Febe E.","family":"van der Flier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline M. B.","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle C.","family":"Cath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeltje M.","family":"Batelaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucianne","family":"Groenink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puck","family":"Duits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Date C.","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton J. L. M.","family":"van Balkom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M. P.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"3","key":"2022_CR1","first-page":"168","volume":"6","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Angermeyer M, Anthony JC, DE Graaf R, Demyttenaere K, Gasquet I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization\u2019s world mental health survey initiative. World Psychiatry. 2005;6(3):168\u201376.","journal-title":"World Psychiatry"},{"issue":"s420","key":"2022_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1600-0047.2004.00325.x","volume":"109","author":"J Alonso","year":"2004","unstructured":"Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;109(s420):21\u20137.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"10","key":"2022_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","volume":"21","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2022_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0022-3999(94)90145-7","volume":"38","author":"E Sou\u011btre","year":"1994","unstructured":"Sou\u011btre E, Lozet H, Cimarosti I, Martin P, Chignon JM, Ad\u00e9s J, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res. 1994;38:151\u201360.","journal-title":"J Psychosom Res"},{"issue":"1","key":"2022_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jad.2011.12.008","volume":"137","author":"M Klein Hofmeijer-Sevink","year":"2012","unstructured":"Klein Hofmeijer-Sevink M, Batelaan NM, Van Megen HJGM, Penninx BW, Cath DC, Van Den Hout MA, et al. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands study of depression and anxiety (NESDA). J Affect Disord. 2012;137(1):106\u201312.","journal-title":"J Affect Disord"},{"issue":"11","key":"2022_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archpsyc.62.11.1249","volume":"62","author":"J Sareen","year":"2005","unstructured":"Sareen J, Cox BJ, Afifi, TO, de Graaf R, Asmundson GJG, ten Have M, Stein M. Anxiety disorders and risk for suicidal ideation and suicide attempts. Arch Gen Psychiatry. 2005;62(11):1249\u201357.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2022_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/acps.12024","volume":"128","author":"SM Hendriks","year":"2013","unstructured":"Hendriks SM, Spijker J, Licht CMM, Beekman ATF, Penninx BWJH. Two-year course of anxiety disorders: different across disorders or dimensions? Acta Psychiatr Scand. 2013;128(3):212\u201321.","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"2022_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.brat.2013.09.009","volume":"51","author":"AT Gloster","year":"2013","unstructured":"Gloster AT, Hauke C, H\u00f6fler M, Einsle F, Fydrich T, Hamm A, et al. Long-term stability of cognitive behavioral therapy effects for panic disorder with agoraphobia: a two-year follow-up study. Behav Res Ther. 2013;51(12):830\u20139.","journal-title":"Behav Res Ther"},{"issue":"1","key":"2022_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jad.2009.06.021","volume":"123","author":"MR Donovan","year":"2010","unstructured":"Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010;123(1):9\u201316.","journal-title":"J Affect Disord"},{"key":"2022_CR10","doi-asserted-by":"crossref","unstructured":"Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017:j3927.","DOI":"10.1136\/bmj.j3927"},{"issue":"4","key":"2022_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0005-7894(05)80040-1","volume":"26","author":"U Feske","year":"1995","unstructured":"Feske U, Chambless DL. Cognitive behavioral versus exposure only treatment for social phobia: a meta-analysis. Behav Ther. 1995;26(4):695\u2013720.","journal-title":"Behav Ther"},{"key":"2022_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","volume":"149","author":"N Singewald","year":"2015","unstructured":"Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther. 2015;149:150\u201390.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2022_CR13","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.brat.2007.06.006","volume":"45","author":"SG Hofmann","year":"2008","unstructured":"Hofmann SG. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther. 2008;45(9):1987\u20132001.","journal-title":"Behav Res Ther"},{"issue":"2","key":"2022_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cpr.2007.04.009","volume":"28","author":"SG Hofmann","year":"2008","unstructured":"Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clin Psychol Rev. 2008;28(2):199\u2013210.","journal-title":"Clin Psychol Rev"},{"issue":"4","key":"2022_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/da.22353","volume":"32","author":"P Duits","year":"2015","unstructured":"Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM, et al. Updated meta-analysis of classical fear conditioning in the anxiety disorders. Depress Anxiety. 2015;32(4):239\u201353.","journal-title":"Depress Anxiety"},{"key":"2022_CR16","unstructured":"Duits P, JMP B, Engelhard IM, Richter J, Huisman-van Dijk HM, Limberg A, et al. Latent fear conditioning trajectories in anxiety disorders and their predictive value on treatment outcome. Manuscr Prep. 2018."},{"issue":"6897","key":"2022_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530\u20134.","journal-title":"Nature"},{"key":"2022_CR18","first-page":"445","volume-title":"Cannabinoid Function in Learning, Memory and Plasticity. Cannabinoids","author":"G Riedel","year":"2005","unstructured":"Riedel G, Davies SN. Cannabinoid Function in Learning, Memory and Plasticity. Cannabinoids. Springer-Verlag: Berlin\/Heidelberg; 2005. p. 445\u201377."},{"key":"2022_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.phrs.2016.07.024","volume":"111","author":"A Berardi","year":"2016","unstructured":"Berardi A, Schelling G, Campolongo P. The endocannabinoid system and post traumatic stress disorder (PTSD): from preclinical findings to innovative therapeutic approaches in clinical settings. Pharmacol Res. 2016;111:668\u201378.","journal-title":"Pharmacol Res"},{"issue":"9","key":"2022_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.90","volume":"2","author":"I Heitland","year":"2012","unstructured":"Heitland I, Klumpers F, Oosting RS, Evers DJJ, Leon Kenemans J, Baas JMP. Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. Transl Psychiatry. 2012;2(9):e162.","journal-title":"Transl Psychiatry"},{"key":"2022_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2012.06.063","volume":"64","author":"CA Rabinak","year":"2013","unstructured":"Rabinak CA, Angstadt M, Sripada CS, Abelson JL, Liberzon I, Milad MR, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013;64:396\u2013402.","journal-title":"Neuropharmacology"},{"key":"2022_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nlm.2013.09.009","volume":"113","author":"CA Rabinak","year":"2014","unstructured":"Rabinak CA, Angstadt M, Lyons M, Mori S, Milad MR, Liberzon I, et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem. 2014;113:125\u201334.","journal-title":"Neurobiol Learn Mem"},{"issue":"4","key":"2022_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","volume":"226","author":"RK Das","year":"2013","unstructured":"Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology. 2013;226(4):781\u201392.","journal-title":"Psychopharmacology"},{"issue":"4","key":"2022_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0269881111431624","volume":"26","author":"F Klumpers","year":"2012","unstructured":"Klumpers F, Denys D, Kenemans JL, Grillon C, Van Der Aart J, Baas JMP. Testing the effects of Delta9-THC and D-cycloserine on extinction of conditioned fear in humans. J Psychopharmacol. 2012;26(4):471\u20138.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"2022_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825\u201336.","journal-title":"Neurotherapeutics"},{"issue":"1607","key":"2022_CR26","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","volume":"367","author":"AC Campos","year":"2012","unstructured":"Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar\u00e3es FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond Ser B Biol Sci. 2012;367(1607):3364\u201378.","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"5","key":"2022_CR27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1021\/cr0782067","volume":"108","author":"K Ahn","year":"2008","unstructured":"Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulat endocannabinoid signaling in the nervous system. Chem Rev. 2008;108(5):1687\u2013707.","journal-title":"Chem Rev"},{"issue":"12","key":"2022_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.euroneuro.2008.07.001","volume":"18","author":"RM Bitencourt","year":"2008","unstructured":"Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol. 2008;18(12):849\u201359.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"2022_CR29","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/npp.2012.63","volume":"37","author":"C Stern","year":"2012","unstructured":"Stern C. A J, Gazarini L, Takahashi RN, Guimar\u00e3es FS, Bertoglio LJ. On disruption of fear memory by reconsolidation blockade: evidence from Cannabidiol treatment. Neuropsychopharmacology. 2012;37(9):2132\u201342.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"2022_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1037\/abn0000266","volume":"126","author":"P Duits","year":"2017","unstructured":"Duits P, Richter J, Baas JMP, Engelhard IM, Limberg-Thiesen A, Heitland I, et al. Enhancing effects of contingency instructions on fear acquisition and extinction in anxiety disorders. J Abnorm Psychol. 2017;126(4):378\u201391.","journal-title":"J Abnorm Psychol"},{"key":"2022_CR31","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1038\/ncomms7395","volume":"6","author":"I Dincheva","year":"2015","unstructured":"Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. Nature Publishing Group. 2015;6:6395.","journal-title":"Nat Commun"},{"issue":"1","key":"2022_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2045-5380-3-4","volume":"3","author":"KJ Lester","year":"2013","unstructured":"Lester KJ, Eley TC. Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord. 2013;3(1):4.","journal-title":"Biol Mood Anxiety Disord"},{"key":"2022_CR33","volume-title":"Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition. (SCID-I\/P)","author":"MB First","year":"2002","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition. (SCID-I\/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002."},{"key":"2022_CR34","volume-title":"De Nederlandse leestest voor volwassenen","author":"B Schmand","year":"1992","unstructured":"Schmand B, Lindeboom J, van Harskamp F. De Nederlandse leestest voor volwassenen. Lisse: Swets & Zeitlinger; 1992."},{"issue":"8","key":"2022_CR35","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s10803-008-0538-x","volume":"38","author":"RA Hoekstra","year":"2008","unstructured":"Hoekstra RA, Bartels M, Cath DC, Boomsma DI. Factor structure, reliability and criterion validity of the autism-spectrum quotient (AQ): a study in Dutch population and patient groups. J Autism Dev Disord. 2008;38(8):1555\u201366.","journal-title":"J Autism Dev Disord"},{"issue":"June","key":"2022_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1176\/appi.ajp.2014.13121625","volume":"171","author":"BO Rothbaum","year":"2014","unstructured":"Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, et al. A randomized, double-blind evaluation of D-Clycoserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan war veterans. Am J Psychiatry. 2014;171(June):640\u20138.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"2022_CR37","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","volume":"63","author":"MM Norberg","year":"2008","unstructured":"Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-Cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118\u201326.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"2022_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang A-G, Buchner A. G*power: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175\u201391.","journal-title":"Behav Res Methods"},{"key":"2022_CR39","volume-title":"Social anxiety: clinical, developmental, and social perspectives","author":"SG Hofmann","year":"2010","unstructured":"Hofmann SG, DiBartolo PM. Social anxiety: clinical, developmental, and social perspectives. New York, NY: Elsevier\/Academic Press; 2010."},{"key":"2022_CR40","volume-title":"Behandeling Paniekstoornis","author":"M Kampman","year":"2012","unstructured":"Kampman M, Keijsers G, Hendriks G. Behandeling Paniekstoornis. Amsterdam: Uitgeverij Boom; 2012."},{"issue":"1","key":"2022_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19\u201327.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"2022_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0005-7967(79)90041-X","volume":"17","author":"I Marks","year":"1979","unstructured":"Marks I, Mathews A. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263\u20137.","journal-title":"Behav Res Ther"},{"issue":"6","key":"2022_CR43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. Others. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893\u20137.","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"2022_CR44","first-page":"490","volume":"78","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio. 1996;78(2):490\u20138.","journal-title":"San Antonio"},{"issue":"6","key":"2022_CR45","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1037\/0022-006X.52.6.1090","volume":"52","author":"DL Chambless","year":"1984","unstructured":"Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment of fear of fear in agoraphobics: the body sensations questionnaire and the agoraphobic cognitions questionnaire. J Consult Clin Psychol. 1984 Dec;52(6):1090\u20137.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"2022_CR46","first-page":"35","volume":"1","author":"SM Turner","year":"1989","unstructured":"Turner SM, Beidel DC, Dancu CV, Stanley MA. An empirically derived inventory to measure social fears and anxiety: the social phobia and anxiety inventory. Psychol Assess A J Consult Clin Psychol. 1989;1(1):35\u201340.","journal-title":"Psychol Assess A J Consult Clin Psychol"},{"issue":"2","key":"2022_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.janxdis.2013.05.003","volume":"28","author":"W Vente de","year":"2014","unstructured":"de Vente W, Majdand\u017ei\u0107 M, Voncken MJ, Beidel DC, B\u00f6gels SM. The SPAI-18, a brief version of the social phobia and anxiety inventory: reliability and validity in clinically referred and non-referred samples. J Anxiety Disord. 2014;28(2):140\u20137.","journal-title":"J Anxiety Disord"},{"issue":"7","key":"2022_CR48","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"2022_CR49","volume-title":"The practice of behavior therapy","author":"J Wolpe","year":"1969","unstructured":"Wolpe J. The practice of behavior therapy. New York: Pergamon Press; 1969."},{"key":"2022_CR50","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Education and Welfare: U.S. Department of Health; 1976."},{"key":"2022_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jocrd.2015.01.006","volume":"6","author":"KG Benito","year":"2015","unstructured":"Benito KG, Walther M. Therapeutic process during exposure: habituation model. J Obsessive Compuls Relat Disord. 2015;6:147\u201357.","journal-title":"J Obsessive Compuls Relat Disord"},{"issue":"11","key":"2022_CR52","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1176\/ajp.154.11.1571","volume":"154","author":"MK Shear","year":"1997","unstructured":"Shear MK, Brown TA, Psy D, Barlow DH, Ph D, Money R, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571\u20135.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2022_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0005-7967(85)90140-8","volume":"23","author":"DL Chambless","year":"1985","unstructured":"Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The mobility inventory for agoraphobia. Behav Res Ther. 1985;23(1):35\u201344.","journal-title":"Behav Res Ther"},{"issue":"6","key":"2022_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0887-6185(02)00134-2","volume":"16","author":"DS Mennin","year":"2002","unstructured":"Mennin DS, Fresco DM, Heimberg RG, Schneier FR, Davies SO, Liebowitz MR. Screening for social anxiety disorder in the clinical setting: using the Liebowitz social anxiety scale. J Anxiety Disord. 2002;16(6):661\u201373.","journal-title":"J Anxiety Disord."},{"key":"2022_CR55","first-page":"301","volume":"28","author":"TK Bouman","year":"1995","unstructured":"Bouman TK. De Agoraphobic Cognition Questionnaire (ACQ). Gedragstherapie. 1995;28:301.","journal-title":"Gedragstherapie."},{"issue":"3","key":"2022_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0887-6185(93)90002-3","volume":"7","author":"RA Steer","year":"1993","unstructured":"Steer RA, Ranieri WF, Beck AT, Clark DA. Further evidence for the validity of the Beck anxiety inventory with psychiatric outpatients. J Anxiety Disord. 1993;7(3):195\u2013205.","journal-title":"J Anxiety Disord."},{"key":"2022_CR57","volume-title":"Manual for the Dutch version of the Beck depression inventory-second edition (BDI-II-NL)","author":"A Does van der","year":"2002","unstructured":"van der Does A. Manual for the Dutch version of the Beck depression inventory-second edition (BDI-II-NL). Amsterdam, NL: Harcourt; 2002."},{"key":"2022_CR58","first-page":"165","volume":"31","author":"TK Bouman","year":"1998","unstructured":"Bouman TK. De Body Sensations Questionnaire (BSQ). Gedragstherapie. 1998;31:165.","journal-title":"Gedragstherapie"},{"key":"2022_CR59","doi-asserted-by":"crossref","unstructured":"Van Zuuren FJ. The Fear Questionnaire. Some data on validity, reliability and layout. Br J Psychiatry. 1988;153(NOV.):659\u2013662.","DOI":"10.1192\/bjp.153.5.659"},{"issue":"6","key":"2022_CR60","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0005-7967(01)00060-2","volume":"40","author":"SL Baker","year":"2002","unstructured":"Baker SL, Heinrichs N, Kim HJ, Hofmann SG. The Liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther. 2002;40(6):701\u201315.","journal-title":"Behav Res Ther"},{"issue":"5","key":"2022_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0022-3956(01)00028-0","volume":"35","author":"K Shear","year":"2001","unstructured":"Shear K, Rucci P, Williams J, Frank E, Grochocinski V, Vander Bilt J, et al. Reliability and validity of the panic disorder severity scale: replication and extension. J Psychiatr Res. 2001;35(5):293\u20136.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"2022_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-244X-11-83","volume":"11","author":"T Forkmann","year":"2011","unstructured":"Forkmann T, Scherer A, Boecker M, Pawelzik M, Jostes R, Gauggel S. The clinical global impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry BioMed Central Ltd. 2011;11(1):83.","journal-title":"BMC Psychiatry BioMed Central Ltd"},{"key":"2022_CR63","volume-title":"Childhood trauma questionnaire: a retrospective self-report manual","author":"DP Bernstein","year":"1998","unstructured":"Bernstein DP, Fink L. Childhood trauma questionnaire: a retrospective self-report manual. San Antonio, TX: The Psychological Corporation; 1998."},{"issue":"3","key":"2022_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94.","journal-title":"Transl Psychiatry"},{"key":"2022_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1472-6963-13-217","volume":"13","author":"C Bouwmans","year":"2013","unstructured":"Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Van der Feltz-Cornelis C, Tan Swan S, et al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv Res. 2013;13:217.","journal-title":"BMC Health Serv Res"},{"key":"2022_CR66","volume-title":"Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg","author":"L Hakkaart-van Roijen","year":"2015","unstructured":"Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan SS. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Zorginstituut Nederland: Diemen; 2015."},{"issue":"3","key":"2022_CR67","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQolGroup","year":"1990","unstructured":"EuroQolGroup. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (New York). 1990;16(3):199\u2013208.","journal-title":"Health Policy (New York)"},{"issue":"8","key":"2022_CR68","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/jamapsychiatry.2016.1132","volume":"73","author":"SG Hofmann","year":"2016","unstructured":"Hofmann SG. Schr\u00f6dinger\u2019s cat and d -Cycloserine to augment exposure therapy\u2014both are alive and dead. JAMA Psychiatry. 2016;73(8):771.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"2022_CR69","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"2022_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1037\/0033-2909.99.1.20","volume":"99","author":"EB Foa","year":"1986","unstructured":"Foa EB, Kozak MJ, Barlow D, Cuthbert B, Foa U, Hallam D, et al. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99(1):20\u201335.","journal-title":"Psychol Bull"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-019-2022-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:10:42Z","timestamp":1581534642000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1186\/s12888-019-2022-x","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the Medical Ethics Committee of the University Medical Centre Utrecht (reference number: NL50898.041.15). Written informed consent will be obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"69"}}